Log In Sign up
The largest database of trusted experimental protocols

Elecsys hbsag 2 assay

Manufactured by Roche
Visit Supplier
Sourced in Germany, Switzerland

The Elecsys HBsAg II assay is a quantitative in vitro diagnostic test used to detect the hepatitis B surface antigen (HBsAg) in human serum or plasma. It is designed for use on the Elecsys and cobas e immunoassay analyzers.

Automatically generated - may contain errors

Lab products found in correlation

Cobas taqman hbv dna assay, by Roche (2 mentions) Cobas ampliprep cobas taqman hbv test, by Roche (2 mentions) Elecsys hbeag assay, by Roche (1 mentions) Elisa, by Abnova (1 mentions) Elecsys hbeag, by Roche (1 mentions) Line probe assay, by Fujirebio (1 mentions) Cobas taqman assay, by Roche (1 mentions) Architect immunoassay, by Abbott (1 mentions) Architect hbsag assay, by Abbott (1 mentions) Elecsys anti hbs 2 assay, by Roche (1 mentions) Spss 22, by IBM (1 mentions) Cobas ampliprep taqman qrt pcr assay, by Roche (1 mentions) Vitros 5600 integrated system, by Ortho Clinical Diagnostics (1 mentions)

13 protocols using elecsys hbsag 2 assay

1

HBx Detection and HBsAg Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols
HBx was detected using anti-HBx mouse monoclonal antibodies (Abcam, Cambridge, UK) and HRP-conjugated anti-mouse IgG secondary antibodies (Cell Signaling Technology, Danvers, MA, USA) by SDS-PAGE and Western Blot. β-actin and histone H3 were used as the protein loading controls for total cell lysate and nuclear protein fraction, respectively. HBsAg in the culture medium was detected by the Elecsys HBsAg II assay (Roche Diagnostics, Indianapolis, IN, USA).
Chong C.K., Cheng C.Y., Tsoi S.Y., Huang F.Y., Liu F., Fung J., Seto W.K., Lai K.K., Lai C.L., Yuen M.F, & Wong D.K. (2020). HBV X protein mutations affect HBV transcription and association of histone-modifying enzymes with covalently closed circular DNA. Scientific Reports, 10, 802.
+ Open protocol
+ Expand
2

Hepatitis B Viral Load Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols
HBV DNA levels were measured by use of the COBAS AmpliPrep/COBAS TaqMan HBV Test, v2.0 assay (Roche Molecular Systems Inc, Pleasanton, CA) according to manufacturer’s protocols. HBsAg concentrations were measured by use of Elecsys HBsAg II assay (Roche Diagnostics GmbH, Mannheim, Germany).
Hsu C.W., Liang K.H., Lin C.L., Wang T.H, & Yeh C.T. (2017). Platelet counts modulate the quantitative relationship between hepatitis B viral DNA and surface antigen concentrations: a cross-sectional study of hematological, histological and viral factors. BMC Infectious Diseases, 17, 9.
+ Open protocol
+ Expand
3

Serum Biochemical Analyses for HBV

Check if the same lab product or an alternative is used in the 5 most similar protocols
Serum biochemical studies were performed using a systemic multiautoanalyzer (Technicon SMAC, Technicon Instruments Corp., Tarrytown, NY). The serum ALT ULN was set by the laboratory at 40 U/L for both males and females. The serum samples were tested for the presence of HBeAg and anti-HBe antibody using radio-immunoassay (Abott Laboratories, North Chicago, IL). HBV DNA was determined by Roche Cobas Tagman HBV DNA assay (detection limit of 12 IU/mL, Roche Diagnostics, Basel, Switzerland), whereas HBsAg levels were quantified using the Elecsys HBsAg II assay (detection limit of 0.05 IU/mL, Roche Diagnostics GmbH, Mannheim, Germany).
Lee I.C., Sun C.K., Su C.W., Wang Y.J., Chang H.C., Huang H.C., Lee K.C., Huang Y.S., Perng C.L., Liu Y.H., Chua C.S., Lin Y.M., Lin H.C, & Huang Y.H. (2015). Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B. Medicine, 94(32), e1341.
+ Open protocol
+ Expand
4

Evaluating Hepatitis B Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fasting plasma was collected from all participants before the initiation of IFN-α treatment. Plasma samples were analyzed for clinical indicators, including the levels of HBsAg, HBeAg, ALT, HBV DNA and HBV genotype. The expression levels of HBsAg and HBeAg were measured by Elecsys HBsAg II assay (Roche Diagnostics, Mannheim, Germany) and Elecsys HBeAg assay (Roche Diagnostics, Mannheim, Germany), respectively, both using an electro-chemiluminescence instrument (E601, Roche). Plasma ALT levels were measured with an automatic biochemical analyzer (P800, Roche). HBV DNA was quantified by a quantitative PCR assay (Qiagen, Shenzhen, China) according to the recommended protocol. HBV genotyping was performed using type A through F genotype specific PCR primers (Biosune, Shanghai, China) .
Li J., Zhang X., Chen L., Zhang Z., Zhang J., Wang W., Wu M., Shi B., Zhang X., Kozlowski M., Hu Y, & Yuan Z. (2017). Circulating miR-210 and miR-22 combined with ALT predict the virological response to interferon-alpha therapy of CHB patients. Scientific Reports, 7, 15658.
+ Open protocol
+ Expand
5

Routine Blood Tests for Hepatitis B

Check if the same lab product or an alternative is used in the 5 most similar protocols
Routine complete blood counts and biochemical tests were performed using a systemic multi-autoanalyzer (Technicon SMAC, Technicon Instruments Corp., Tarrytown, NY) at baseline and monthly during therapy. The serum HBeAg and anti-HBe antibody levels were measured by radio-immunoassay (Abott Laboratories, North Chicago, IL). HBsAg was quantified by Elecsys HBsAg II assay (Roche Diagnostics GmbH, Mannheim, Germany). HBV viral load was determined by a PCR-based method, namely the Roche Cobas Taqman HBV DNA assay (detection limit of 12 IU/mL, Roche Diagnostics, Switzerland).
Wang Y.C., Yang S.S., Su C.W., Wang Y.J., Lee K.C., Huo T.I., Lin H.C, & Huang Y.H. (2016). Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Scientific Reports, 6, 29605.
+ Open protocol
+ Expand
6

Sensitive HBsAg Detection in OBI

Check if the same lab product or an alternative is used in the 5 most similar protocols
We confirmed negative HBsAg serology in all samples with detectable HBV DNA using a chemiluminescent microparticle immunoassay (Architect, Abbott; LOD, 0.1 IU/L) or the ultrasensitive Elecsys HBsAg II assay (Roche; LOD, 0.05 IU/L). All OBI-positive samples were tested for anti-HBc using an enzyme-linked immunosorbent assay (ELISA; Abnova).
Ndow G., Cessay A., Cohen D., Shimakawa Y., Gore M.L., Tamba S., Ghosh S., Sanneh B., Baldeh I., Njie R., D’Alessandro U., Mendy M., Thursz M., Chemin I, & Lemoine M. (2021). Prevalence and Clinical Significance of Occult Hepatitis B Infection in The Gambia, West Africa. The Journal of Infectious Diseases, 226(5), 862-870.
+ Open protocol
+ Expand
7

Quantitative Detection of HBV Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols
Serum HBV-DNA was quantified by COBAS AmpliPrep-Cobas TaqMan HBV test (Roche, Basel, CH). HBsAg quantification was carried out by Elecsys®HBsAgII assay (Roche, Basel, CH), with a lower limit of detection of 0.05 IU/ml while HBeAg qualitative detection by Elecsys®HBeAg (Roche, Basel, CH).
Piermatteo L., D’Anna S., Bertoli A., Bellocchi M., Carioti L., Fabeni L., Alkhatib M., Frazia S.L., Lichtner M., Mastroianni C., Sanctis G.D., Marignani M., Pasquazzi C., Iapadre N., Parruti G., Cappiello G., Vecchiet J., Malagnino V., Grelli S., Ceccherini-Silbertein F., Andreoni M., Sarmati L., Svicher V, & Salpini R. (2023). Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies. Emerging Microbes & Infections, 12(1), 2219347.
+ Open protocol
+ Expand
8

Comprehensive HBV Resistance Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Serum HBV DNA levels were measured using Cobas Taqman assay (Roche Diagnostics, Branchburg, NJ) with the lower limit of detection of 20 IU/ml. Resistance profile was performed using a line probe assay (Innogenetics NV, Gent, Belgium), with both line probe assay DR version 2 and 3 used to identify the amino acids at codons rt173, rt180, rt240 and rt184, and rt202 and rt250, respectively. Genotypic resistance to entecavir was defined by the presence of three viral mutations: rtL180M, rtM204V/I, and one of the following: rtT184S/C/G/A, rtS202G/C/I, or rtM250V. Serum HBeAg, antibody to HBeAg and antibody to HBsAg were measured by the Architect Immunoassays (Abbott Laboratories, Chicago, IL). Serum HBsAg levels were performed using Elecsys HBsAg II Assay (Roche Diagnostics, Branchburg, NJ), with a linear range of 0.05–52,000 IU/ml. Samples with levels higher than 52,000 IU/ml were tested at a dilution of 1:100 according to the manufacturer’s instruction. The HBcrAg levels were determined by the Lumipulse G HBcrAg Chemiluminescence Enzyme Immunoassay (Fujirebio, Tokyo, Japan). The dynamic range of the assay ranges from 1 to 1 × 104 kU/ml. Samples with HBcrAg>104 kU/ml were retested at dilution of 1:100 according to the manufacturer’s instruction. In the present study, the lower cutoff value of HBcrAg concentration is 1 kU/ml.
Lam Y.F., Seto W.K., Wong D., Cheung K.S., Fung J., Mak L.Y., Yuen J., Chong C.K., Lai C.L, & Yuen M.F. (2017). Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels. Clinical and Translational Gastroenterology, 8(10), e125-.
+ Open protocol
+ Expand
9

Hepatitis B Virus Biomarkers in Chemotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following parameters were collected: age, sex, body mass index (BMI), diabetes mellitus (DM), hypertension, cancer types, duration and regimen of chemotherapy, serum HBV DNA, HBsAg, HBeAg, BUN, creatinine, albumin, total bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Serum biochemistry tests were performed using a systemic multi-autoanalyzer (Technicon SMAC, Technicon Instruments Corp., Tarrytown, NY, USA). HBV DNA levels were determined by Roche Cobas Taqman HBV DNA assay (detection limit of 20 IU/mL, Roche Diagnostics, Switzerland). Quantitative HBsAg level was measured by the Elecsys HBsAg II assay (Roche Diagnostics, Mannheim, Germany) or Abbott Architect HBsAg assay (Abbott Diagnostics, Abbott Park, IL, USA) with a detection limit of 0.05 IU/mL.
Lee I.C., Lan K.H., Su C.W., Li C.P., Chao Y., Lin H.C., Hou M.C, & Huang Y.H. (2022). Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy. International Journal of Molecular Sciences, 23(19), 11335.
+ Open protocol
+ Expand
10

Quantification of HBV-DNA and HBsAg

Check if the same lab product or an alternative is used in the 5 most similar protocols
Serum HBV-DNA was quantified using the COBAS AmpliPrep-COBAS TaqMan HBV test (Roche Diagnostics, Basel, CH, Switzerland), with a lower limit of detection of 20 IU/mL and HBsAg was quantified using the Elecsys®HBsAgII assay (Roche Diagnostics, Basel, CH, Switzerland), with a lower limit of detection of 0.05 IU/mL. HDV infection was diagnosed by the presence of anti-HDV antibodies and HDV RNA in plasma, as previously described [23 (link)]. Liver function tests were performed by standard commercial methods.
Brancaccio G., Salpini R., Piermatteo L., Surdo M., Fini V., Colagrossi L., Cantone M., Battisti A., Oda Y., Di Carlo D., Ceccherini-Silberstein F., Perno C.F., Gaeta G.B, & Svicher V. (2021). An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression. Microorganisms, 9(4), 752.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!